Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00401-006-0065-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperprolactinemia complicated with peliosis hepatis: One case report and review of literature.
Medicine (Baltimore)
January 2025
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rationale: Peliosis hepatis (PH) is a rare disease with few clinical reports and complex etiology. However, there have been no reports of hyperprolactinemia (HPRL) leading to PH at present. This paper, through case reports, expands the understanding of the etiology of PH and the pathological damage effect of prolactin (PRL).
View Article and Find Full Text PDFCorrelation between MRI findings of pituitary gland and prolactin level among hyperprolactinemia adult female Saudi patients in rural areas: A retrospective multicentric study.
Medicine (Baltimore)
January 2025
Department of Urology, School of Medicine, Ibb University, Ibb, Yemen.
Identifying the prolactin threshold that necessitates pituitary magnetic resonance imaging (MRI) in patients with hyperprolactinemia remains challenging. Therefore, developing standards for serum prolactin level criteria to predict prolactinoma is critical. This study aimed to investigate the correlation between hyperprolactinemia and the presence of pituitary adenoma among Saudi female patients with verified prolactin levels.
View Article and Find Full Text PDFScreening with Metoclopramide Test to Reduce Unnecessary Pituitary Magnetic Resonance Studies in Moderate Hyperprolactinemia.
J Appl Lab Med
January 2025
Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
Background: In prolactinoma diagnosis, current guidelines recommend prolactin (PRL) assessment, considering values exceeding 200 ng/mL highly suggestive of prolactinoma. However, subtler hyperprolactinemia is more common, and to rule out potential prolactinomas, pituitary resonance magnetic imaging (MRI) studies are necessary. These present limitations in terms of availability, costs, and delays in diagnosis.
View Article and Find Full Text PDFRET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly.
Endocr Relat Cancer
January 2025
C Alvarez, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
The discovery of RET mutations in Multiple Endocrine Neoplasia 2A (MEN2A) in 1993 ignited a revolution in our understanding of this versatile receptor. Since then, RET's influence has expanded to encompass diverse organs, including the pituitary gland. This review explores the multifaceted role of RET in somatotrophs, focusing on two opposing pathways: proliferation versus differentiation and apoptosis.
View Article and Find Full Text PDFGenotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.
Front Endocrinol (Lausanne)
December 2024
Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Fukushima, Japan.
Article Synopsis
- Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder characterized by tumors in multiple endocrine glands, but some patients may lack the genetic markers typically associated with the condition.
- A 56-year-old woman with a history of a macroprolactinoma, primary hyperparathyroidism, and a cortisol-producing adrenal adenoma was diagnosed with MEN1 despite being genotype-negative, raising concerns about the reliability of genetic testing.
- The case highlights that genotype-negative MEN1 can involve serious complications and emphasizes the importance of recognizing clinical symptoms like glucose intolerance and tumor manifestations to avoid delayed diagnoses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!